文献速递冠心病血脂与心血管预防

强化与他汀初治患者斑块逆转:FLOWPROMOTE随机试验预设分析

Intensive vs More Intensive Lipid-Lowering Therapy and Plaque Regression in Statin-Naive Patients: Prespecified Analyses From the FLOWPROMOTE Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-10-30

FLOWPROMOTE预设二次分析纳入104例他汀初治稳定冠心病患者,随机接受阿托伐他汀40mg或瑞舒伐他汀40mg联合依折麦布10mg治疗18个月。更强化治疗组LDL-C降幅更大,总斑块体积和非钙化斑块体积逆转更显著,且LDL-C达标水平与斑块逆转呈线性相关。

要点

  • 更强化降脂(瑞舒伐他汀40mg+依折麦布10mg)较阿托伐他汀40mg显著缩小总斑块和非钙化斑块体积。
  • 更强化组总斑块逆转发生率90%、非钙化斑块逆转98%,均高于强化组。
  • LDL-C达标水平越低,总斑块和非钙化斑块逆转幅度越大。

核心结论

  • 在他汀初治稳定冠心病患者中,更强化降脂治疗较轻强化治疗带来更显著的总斑块和非钙化斑块逆转。
  • 斑块逆转程度与 achieved LDL-C 水平呈线性相关,支持强化降脂可能部分逆转冠状动脉粥样硬化。

研究设计与样本

  • FLOWPROMOTE为多中心随机临床试验,纳入他汀初治新诊断稳定冠心病患者,定义为冠脉CTA狭窄大于50%且CT血流储备分数小于等于0.80。
  • 本分析共104例,平均年龄64(9)岁,男性82例(79%),强化组52例,更强化组52例。
  • 基线、9个月和18个月行冠脉CTA,比较总斑块体积、非钙化斑块体积和钙化斑块体积变化。

主要发现

  • LDL-C从119.7降至69.5 mg/dL(-38%)见于强化治疗,从127.4降至42.5 mg/dL(-65%)见于更强化治疗,组间P < .001。
  • 18个月时总斑块体积更强化组减少-69.8 mm3(-21.1%),强化组减少-39.0 mm3(-13.6%),组间差-30.9 mm3(95%CI -57.2至-4.5 mm3;P = .02)。
  • 非钙化斑块体积更强化组减少-82.3 mm3(-28.2%),强化组减少-53.5 mm3(-20.0%),组间差-28.9 mm3(95%CI -53.2至-4.6 mm3;P = .02)。
  • 总斑块逆转发生率更强化组90%(47/52)对强化组75%(38/51),P = .05;非钙化斑块逆转发生率98%(51/52)对77%(39/51),P = .001。
  • 钙化斑块体积两组均增加且相似。

关键数值与推荐

  • 更强化降脂方案为瑞舒伐他汀40 mg联合依折麦布10 mg,强化方案为阿托伐他汀40 mg,疗程18个月。
  • 稳定冠心病入组标准为冠脉CTA狭窄大于50%且CT血流储备分数小于等于0.80。

临床怎么用

  • 对他汀初治稳定冠心病患者,可考虑更强化降脂策略以促进斑块逆转。
  • 治疗中应关注LDL-C达标水平,越低可能越有利于总斑块和非钙化斑块逆转。

局限性

  • 本分析为预设二次影像终点分析,样本量104例,结论需更大规模研究验证。
  • 原文未报告临床硬终点,斑块逆转的临床获益尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prior imaging studies (predominantly using intravascular ultrasound) have demonstrated modest plaque regression with lipid-lowering therapy in stable coronary artery disease (CAD). The effect of initiating intensive lipid-lowering therapy on coronary plaque regression across the entire coronary tree in treatment-naive patients remains uncertain. OBJECTIVE: To report the prespecified secondary imaging end points of the FLOWPROMOTE trial by comparing the effects of intensive vs more intensive lipid-lowering therapy on plaque regression in statin-naive patients with stable CAD and to assess the association between achieved low-density lipoprotein cholesterol (LDL-C) levels and plaque regression. DESIGN, SETTING, AND PARTICIPANTS: FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD, defined by a coronary computed tomography angiography (CTA) stenosis greater than 50% and fractional flow reserve CT less than or equal to 0.80. Coronary CTA was performed at baseline and repeated at 9 and 18 months. Study data were analyzed from February 2025 to January 2026. INTERVENTIONS: Patients were randomized to intensive lipid-lowering therapy (atorvastatin 40 mg) or more intensive lipid-lowering therapy (rosuvastatin 40 mg plus ezetimibe 10 mg) for 18 months. MAIN OUTCOMES AND MEASURES: Prespecified secondary end points included changes in total plaque volume (TPV), noncalcified plaque volume (NCPV), and calcified plaque volume (CPV) across all coronary vessels at 9 and 18 months compared with baseline. RESULTS: A total of 104 patients (mean [SD] age, 64 [9] years; 82 male [79%]) were included in this analysis, with 52 patients in the intensive group and 52 patients in the more intensive group. LDL-C levels decreased from 119.7 to 69.5 mg/dL (-38%) with intensive therapy and from 127.4 to 42.5 mg/dL (-65%) with more intensive therapy (between-group P < .001). At 18 months, both TPV and NCPV decreased in both groups, with significantly greater regression in the more intensive-therapy group. TPV was reduced by -69.8 mm3 (-21.1%) with more intensive therapy vs -39.0 mm3 (-13.6%) with intensive therapy (between-group difference, -30.9 mm3; 95% CI, -57.2 to -4.5 mm3; P = .02), and NCPV was reduced by -82.3 mm3 (-28.2%) vs -53.5 mm3 (-20.0%), respectively (between-group difference, -28.9 mm3; 95% CI, -53.2 to -4.6 mm3; P = .02). CPV increased similarly in both groups. Regression of TPV occurred in 90% of patients receiving more intensive therapy compared with 76% receiving intensive therapy (47 of 52 [90%] vs 38 of 51 [75%]; P = .05), and regression of NCPV was observed in 98% vs 77% (51 of 52 [98%] vs 39 of 51 [77%]; P =.001). Lower achieved LDL-C levels were linearly associated with greater regression of TPV and NCPV. CONCLUSIONS AND RELEVANCE: This secondary analysis of the FLOWPROMOTE randomized clinical trial demonstrated that in statin-naive patients with CAD, more intensive lipid-lowering therapy was associated with significantly greater regression of total and noncalcified coronary plaque burden compared with intensive therapy. The extent of plaque regression was related to achieved LDL-C levels, supporting the potential for partial reversal of coronary atherosclerosis with intensive lipid reduction. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04737408.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Mortensen MB, Iraqi N, Sand NPR, et al. Intensive vs More Intensive Lipid-Lowering Therapy and Plaque Regression in Statin-Naive Patients: Prespecified Analyses From the FLOWPROMOTE Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42961412. doi:10.1001/jamacardio.2026.4788

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。